Human Cancer Biology High-Resolution Array CGH and Gene Expression Pro fi ling of Alveolar Soft Part Sarcoma

Purpose: Alveolar soft part sarcoma (ASPS) is a soft tissue sarcoma with poor prognosis, and little molecular evidence exists for its origin, initiation, and progression. The aim of this study was to elucidate candidate molecular pathways involved in tumor pathogenesis. Experimental Design: We employed high-throughput array comparative genomic hybridization (aCGH) and cDNA-Mediated Annealing, Selection, Ligation, and Extension Assay to profile the genomic and expression signatures of primary andmetastatic ASPS from17 tumors derived from11patients.Weused an integrative bioinformatics approach to elucidate the molecular pathways associated with ASPS progression. FISH was performed to validate the presence of the t(X;17)(p11.2;q25) ASPL–TFE3 fusion and, hence, confirm the aCGH observations. Results: FISH analysis identified the ASPL–TFE3 fusion in all cases. aCGH revealed a higher number of numerical aberrations inmetastatic tumors relative to primaries, but failed to identify consistent alterations in either group. Gene expression analysis highlighted 1,063 genes thatwere differentially expressed between the two groups. Gene set enrichment analysis identified 16 enriched gene sets (P < 0.1) associated with differentially expressed genes. Notable among these were several stem cell gene expression signatures and pathways related to differentiation. In particular, the paired box transcription factor PAX6was upregulated in the primary tumors, along with several genes whosemouse orthologs have previously been implicated in Pax6 DNA binding during neural stem cell differentiation. Conclusion: In addition to suggesting a tentative neural line of differentiation for ASPS, these results implicate transcriptional deregulation from fusion genes in thepathogenesis of ASPS.ClinCancer Res; 20(6);

[1]  C. Leslie,et al.  Combining integrated genomics and functional genomics to dissect the biology of a cancer‐associated, aberrant transcription factor, the ASPSCR1–TFE3 fusion oncoprotein , 2013, The Journal of pathology.

[2]  P. Komminoth,et al.  Pathology and Genetics of Tumours of Soft Tissue and Bone , 2013 .

[3]  An-Qin Zhang,et al.  Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels. , 2012, International journal of oncology.

[4]  Wei Liu,et al.  Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[5]  P. Mukeňsnabl,et al.  Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease. , 2011, Anticancer research.

[6]  P. V. van Diest,et al.  Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer , 2011, The Journal of pathology.

[7]  Z. Ling,et al.  Possible role of Pax-6 in promoting breast cancer cell proliferation and tumorigenesis. , 2011, BMB reports.

[8]  Jürgen Hoffmann,et al.  Interleukin‐6 promotes tumorigenesis by altering DNA methylation in oral cancer cells , 2011, International journal of cancer.

[9]  F. Algaba,et al.  Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. , 2011, European urology.

[10]  J. Rubenstein,et al.  Lhx6 and Lhx8 Coordinately Induce Neuronal Expression of Shh that Controls the Generation of Interneuron Progenitors , 2011, Neuron.

[11]  Ying Jin,et al.  Pax6 is a human neuroectoderm cell fate determinant. , 2010, Cell stem cell.

[12]  J. Rubenstein,et al.  The Level of the Transcription Factor Pax6 Is Essential for Controlling the Balance between Neural Stem Cell Self-Renewal and Neurogenesis , 2009, PLoS genetics.

[13]  T. Izumi,et al.  Molecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcoma. , 2009, Cancer genetics and cytogenetics.

[14]  R. Shoemaker,et al.  BMC Cancer BioMed Central Research article Gene expression profiling of alveolar soft-part sarcoma (ASPS) , 2009 .

[15]  A. Lazar,et al.  Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma , 2007, Clinical Cancer Research.

[16]  P. Schirmacher,et al.  Detection of the ASPSCR1–TFE3 gene fusion in paraffin‐embedded alveolar soft part sarcomas , 2007, Histopathology.

[17]  A. Folpe,et al.  Alveolar soft-part sarcoma: a review and update , 2006, Journal of Clinical Pathology.

[18]  L. Guillou,et al.  Alveolar soft-part sarcoma of the uterine corpus: Histological, immunocytochemical and ultrastructural study of a case , 2005, Virchows Archiv A.

[19]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[20]  M. Ladanyi,et al.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.

[21]  Alfons Meindl,et al.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.

[22]  H. Miki,et al.  RT-PCR Suggests Human Skeletal Muscle Origin of Alveolar Soft-Part Sarcoma , 2000, Oncology.

[23]  R. Zarbo,et al.  Immunohistochemical profile of myogenin and MyoD1 does not support skeletal muscle lineage in alveolar soft part sarcoma. , 1999, Archives of pathology & laboratory medicine.

[24]  S. Knuutila,et al.  DNA copy number changes in alveolar soft part sarcoma: a comparative genomic hybridization study. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  A. Gown,et al.  Does alveolar soft-part sarcoma exhibit skeletal muscle differentiation? An immunocytochemical and biochemical study of myogenic regulatory protein expression. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  H. Correa,et al.  Trisomy 8 in alveolar soft part sarcoma. , 1995, Cancer genetics and cytogenetics.

[27]  V. Eusebi,et al.  Alveolar soft-part sarcoma: a new type of rhabdomyosarcoma? , 1994, Seminars in diagnostic pathology.

[28]  Mark L. Greenberg,et al.  Molecular genetic, cytogenetic, and immunohistochemical characterization of alveolar soft‐part sarcoma: Implications for cell of origin , 1992, Cancer.

[29]  P. Houghton,et al.  MyoD1 protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature. , 1991, The American journal of surgical pathology.

[30]  T. Hasegawa,et al.  Cytoskeletal properties of alveolar soft part sarcoma. , 1990, Human pathology.

[31]  H. Evans Alveolar soft‐part sarcoma. A study of 13 typical examples and one with a histologically atypical component , 1985, Cancer.